US · BIAF · MEDICAL - DIAGNOSTICS & RESEARCH
bioAffinity Technologies, Inc. (BIAF) intrinsic value and stock valuation
$1.65as of 2026-11-21 · Mkt cap 3.33M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
bioAffinity Technologies, Inc. DCF and intrinsic value
InvestorsCraft values BIAF with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from BIAF’s statements →
bioAffinity Technologies, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.16M | $9.36M | $2.53M | $0.00 | $0.00 |
| Operating income | -$-10.57M | -$-8.95M | -$-7.97M | -$-4.01M | -$-2.21M |
| Net income | -$-14.91M | -$-9.04M | -$-7.94M | -$-8.15M | -$-6.33M |
| EPSd | -$-8.67M | -$-22.6M | -$-27.38M | -$-54.33M | -$-70.33M |
| Operating cash flow | -$-9.33M | -$-7.26M | -$-6.04M | -$-4.07M | -$-2.05M |
| Capital expenditure | -$-60K | -$-80K | -$-20K | -$-220K | -$0.00 |
| Free cash flow | -$-9.39M | -$-7.34M | -$-6.06M | -$-4.29M | -$-2.05M |
| Total assets | $11M | $6.51M | $8.22M | $12.2M | $1.45M |
| Total debt | $1.16M | $1.5M | $1.58M | $250K | $11.4M |
| Net debt | -$-5.29M | $400K | -$-1.24M | -$-11.16M | $10M |
| Total equity | $7.28M | $2.6M | $4.86M | $11M | -$-15.79M |
| Cash and short-term investments | $6.45M | $1.11M | $2.82M | $11.4M | $1.36M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.16M | $9.36M | $2.53M | $0.00 | $0.00 |
| Cost of revenue | $4.73M | $5.98M | $1.74M | $0.00 | $0.00 |
| Gross profit | $1.43M | $3.38M | $790K | $0.00 | -$0.00 |
| Research and development expenses | $2.09M | $1.78M | $1.73M | $1.52M | $1.14M |
| Selling, general and administrative expenses | $9.91M | $9.94M | $6.79M | $2.48M | $1.07M |
| Other expenses | $0.00 | $610K | $250K | $10K | $0.00 |
| Operating expenses | $12M | $12.3M | $8.77M | $4.02M | $2.2M |
| Cost and expenses | $16.7M | $18.3M | $10.5M | $4.02M | $2.21M |
| Interest income | $20K | $20K | $120K | $50K | $0.00 |
| Interest expense | $40K | $90K | $40K | $2.53M | $1M |
| Depreciation and amortization | $500K | $610K | $250K | $10K | $0.00 |
| Ebitda | -$-14.32M | -$-8.33M | -$-7.63M | -$-5.61M | -$-5.32M |
| Operating income | -$-10.57M | -$-8.95M | -$-7.97M | -$-4.01M | -$-2.21M |
| Total other income/expenses, net | -$-4.29M | -$-80K | $60K | -$-4.14M | -$-4.12M |
| Income before tax | -$-14.87M | -$-9.03M | -$-7.92M | -$-8.15M | -$-6.32M |
| Income tax expense | $40K | $10K | $20K | $0.00 | $0.00 |
| Net income | -$-14.91M | -$-9.04M | -$-7.94M | -$-8.15M | -$-6.33M |
| Weighted average shares outstanding | $1.72M | $400K | $290K | $150K | $90K |
| Weighted average diluted shares outstanding | $1.72M | $400K | $290K | $150K | $90K |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $6.45M | $1.11M | $2.82M | $11.4M | $1.36M |
| Net receivables | $540K | $1.14M | $810K | $10K | $0.00 |
| Inventory | $50K | $30K | $20K | $10K | $0.00 |
| Total current assets | $7.57M | $2.7M | $3.97M | $12M | $1.44M |
| Property, plant and equipment, net | $1.26M | $1.62M | $1.99M | $210K | $0.00 |
| Goodwill and intangible assets | $2.12M | $2.18M | $2.24M | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $3.4M | $3.82M | $4.25M | $220K | $20K |
| Total assets | $11M | $6.51M | $8.22M | $12.2M | $1.45M |
| Accounts payable | $760K | $990K | $600K | $350K | $230K |
| Short-term debt | $380K | $690K | $920K | $250K | $11.2M |
| Deferred revenue | $40K | $20K | $30K | $0.00 | $0.00 |
| Total current liabilities | $2.91M | $3.1M | $2.25M | $1.14M | $13M |
| Long-term debt | $780K | $810K | $1.12M | $0.00 | $160K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $780K | $810K | $1.12M | $0.00 | $4.2M |
| Capital lease obligations | $740K | $1.31M | $1.58M | $0.00 | $0.00 |
| Total liabilities | $3.68M | $3.91M | $3.37M | $1.14M | $17.2M |
| Common stock | $30K | $110K | $70K | $60K | $20K |
| Retained earnings | -$-68.55M | -$-53.64M | -$-44.6M | -$-36.67M | -$-28.51M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | -$-4.04M |
| Total equity | $7.28M | $2.6M | $4.86M | $11M | -$-15.79M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $1.16M | $1.5M | $1.58M | $250K | $11.4M |
| Net debt | -$-5.29M | $400K | -$-1.24M | -$-11.16M | $10M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-14.91M | -$-9.04M | -$-7.94M | -$-8.15M | -$-6.33M |
| Depreciation and amortization | $500K | $610K | $250K | $10K | $0.00 |
| Stock-based compensation | $670K | $990K | $750K | $250K | $40K |
| Change in working capital | $590K | $180K | $900K | $110K | $630K |
| Accounts receivable | $600K | -$-330K | $310K | -$-10K | $0.00 |
| Inventory | -$-30K | -$-10K | -$-10K | -$-10K | $0.00 |
| Accounts payable | -$-230K | $380K | -$-10K | $110K | $40K |
| Net cash provided by operating activities | -$-9.33M | -$-7.26M | -$-6.04M | -$-4.07M | -$-2.05M |
| Investments in property, plant and equipment | -$-60K | -$-80K | -$-20K | -$-220K | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | -$-2.19M | $0.00 | $0.00 |
| Net cash used for investing activities | -$-60K | -$-80K | -$-2.21M | -$-220K | $0.00 |
| Common stock issued | $15.1M | $4.35M | $0.00 | $6.03M | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $14.7M | $5.63M | -$-340K | $14.3M | $3.33M |
| Net change in cash | $5.34M | -$-1.72M | -$-8.59M | $10.1M | $1.28M |
| Cash at end of period | $6.45M | $1.11M | $2.82M | $11.4M | $1.36M |
| Operating cash flow | -$-9.33M | -$-7.26M | -$-6.04M | -$-4.07M | -$-2.05M |
| Capital expenditure | -$-60K | -$-80K | -$-20K | -$-220K | -$0.00 |
| Free cash flow | -$-9.39M | -$-7.34M | -$-6.06M | -$-4.29M | -$-2.05M |
Line items
Line items
Line items
About bioAffinity Technologies, Inc.
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
- CEO
- Maria Zannes
- Employees
- 57
- Beta
- -1.11
Explore
Frequently asked questions
What is the intrinsic value of bioAffinity Technologies, Inc. (BIAF)?
bioAffinity Technologies, Inc. (BIAF) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is BIAF undervalued?
BIAF trades at a price of $1.65 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.